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Abstract
The influenza A virus RNA polymerase is a heterotrimeric complex responsible for viral genome transcription and replication
in the nucleus of infected cells. We recently carried out a proteomic analysis of purified polymerase expressed in human
cells and identified a number of polymerase-associated cellular proteins. Here we characterise the role of one such host
factors, SFPQ/PSF, during virus infection. Down-regulation of SFPQ/PSF by silencing with two independent siRNAs reduced
the virus yield by 2–5 log in low-multiplicity infections, while the replication of unrelated viruses as VSV or Adenovirus was
almost unaffected. As the SFPQ/PSF protein is frequently associated to NonO/p54, we tested the potential implication of the
latter in influenza virus replication. However, down-regulation of NonO/p54 by silencing with two independent siRNAs did
not affect virus yields. Down-regulation of SFPQ/PSF by siRNA silencing led to a reduction and delay of influenza virus gene
expression. Immunofluorescence analyses showed a good correlation between SFPQ/PSF and NP levels in infected cells.
Analysis of virus RNA accumulation in silenced cells showed that production of mRNA, cRNA and vRNA is reduced by more
than 5-fold but splicing is not affected. Likewise, the accumulation of viral mRNA in cicloheximide-treated cells was reduced
by 3-fold. In contrast, down-regulation of SFPQ/PSF in a recombinant virus replicon system indicated that, while the
accumulation of viral mRNA is reduced by 5-fold, vRNA levels are slightly increased. In vitro transcription of recombinant
RNPs generated in SFPQ/PSF-silenced cells indicated a 4–5-fold reduction in polyadenylation but no alteration in cap
snatching. These results indicate that SFPQ/PSF is a host factor essential for influenza virus transcription that increases the
efficiency of viral mRNA polyadenylation and open the possibility to develop new antivirals targeting the accumulation of
primary transcripts, a very early step during infection.
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Introduction
The influenza A viruses belong to the family Orthomyxoviridae and
contain a segmented, single-stranded RNA genome of negative
polarity (for a review see [1]. Each of the genomic RNA segments
is encapsidated in a ribonucleoprotein particle (RNP) containing
the polymerase complex and a number of nucleoprotein (NP)
monomers, depending on their size [2,3]. Contrary to many other
RNA viruses, the influenza virus RNPs are transcribed and
replicated in the nucleus of infected cells. The enzyme responsible
for these activities is the viral polymerase, a heterotrimer that
comprises the PB1, PB2 and PA subunits [4–6]. The PB1 subunit
acts as polymerase [7,8] while PB2 and PA are responsible for cap-
binding and cap-snatching, respectively [9–12]. The heterotrimer
has a compact structure [2,13–15] and is required for both
transcription and replication [7,16–19]. The polymerase complex
can be found associated to the RNP structure or in a soluble form
[20], the latter being able to oligomerise in vivo [21,22]. Along the
years, a number of human cell factors have been described as
interactors of influenza virus polymerase and in some specific cases
their role in virus replication has been studied [23–36].
In one such studies, we identified the human SFPQ/PSF factor
as associated in vivo to influenza virus polymerase by proteomic
analysis of purified complexes [34]. Human SFPQ/PSF is a
nuclear multifunctional protein that has been implicated in a series
of steps in the human gene expression pathway (for a review, see
[37]. It was first described as associated to the polypyrimidine
tract-binding protein (PTB) [38] and contains regions rich in
arginine/glycine and proline/glutamine close to its N-terminus as
well as two RRMs located more C-terminal. SFPQ/PSF can be
found as a heterodimer with p54nrb/NonO, a protein that is
highly homologous to the SFPQ/PSF C-terminal half. The
SFPQ/PSF-p54nrb/NonO heterodimer co-purifies with DNA
topoisomerase and interacts with RAD1 recombinase, leading to
the stimulation of nucleic acid strand transfer and the cleavage/
religation steps [39–43]. In addition, several reports have shown
that SFPQ/PSF and/or p54nrb/NonO can regulate cellular
transcription in a variety of genes (reviewed in [37]. In agreement
with the SFPQ/PSF association with PTB, its binding has been
reported to elements in the splicing machinery, like the U4/U6-
U5 tri-snRNP and many other splicing factors [44–46] and the
RNA pol II CTD [47], probably in a RRM-dependent manner
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shown to stimulate the splicing of mRNAs transcribed by strong
transcriptional activators and to control alternative splicing
[49,50]. In spite of the above mentioned associations, most of
SFPQ/PSF-p54nrb/NonO can be found in the ‘‘nuclear matrix’’
fraction [51], consistent with the proposed role for the heterodimer
in the specific retention in the nuclear matrix of RNA which has
been A.I hyperedited [37,52].
In addition to these many potential functions assigned to
SFPQ/PSF or the SFPQ/PSF-p54nrb/NonO heterodimer, the
former has been shown to bind specifically to a defined stem-loop
in hepatitis delta RNA [53] and the 39-end of HCV genome [54],
while the latter inhibits the transport and expression of HIV
mRNAs containing the instability region (INS) [55]. Here we have
analysed the role of SFPQ/PSF in the influenza virus infection.
Silencing the SFPQ/PSF gene, but not p54nrb/NonO, strongly
reduced virus multiplication. The accumulation of viral genomic
vRNA and mRNA as well as viral proteins was reduced, probably
as a consequence of the inhibition of primary and secondary
transcription, but normal splicing of virus mRNA was observed. In
vitro transcription of recombinant RNPs generated in SFPQ-
silenced cells resulted in reduced levels of viral poly A
+ RNA.
These results are consistent with a role for SFPQ/PSF during the
polyadenylation step in the synthesis of viral mRNAs from the
parental RNP templates, the earliest nuclear step in virus
replication cycle, as well as during secondary transcription.
Results/Discussion
A proteomic analysis of the intracellular complexes formed by
recombinant influenza virus polymerase revealed a series of
human proteins that were stably associated to the viral enzyme
[34]. One of such associated factors was SFPQ/PSF, a
multifunctional nuclear protein involved in transcription, post-
transcriptional processing of mRNAs and DNA rearrangements
[37]. To study the role of SFPQ/PSF in influenza virus replication
we first analysed the expression and localisation of the protein
along the infection cycle. Cultures of A549 cells were infected with
VIC influenza virus at high multiplicity and total cell extracts were
prepared at various times thereafter. The accumulation of SFPQ/
PSF was determined by Western-blot using specific antibodies and
is shown in Figure 1A. No changes in the level of expression of the
Authors Summary
The influenza A viruses cause annual epidemics and
occasional pandemics of respiratory infections that may
be life threatening. The viral genome contains 8 RNA
molecules forming ribonucleoproteins that replicate and
transcribe in the nucleus of infected cells. Influenza viruses
are intracellular parasites that need the host cell machinery
to replicate. To better understand this virus-cell interplay
we purified the viral RNA polymerase expressed in human
cells and identified several specifically associated cellular
proteins. Here we characterise the role of one of them, the
proline-glutamine rich splicing factor (SFPQ/PSF). Down-
regulation of SFPQ/PSF indicated that it is essential for
virus multiplication. Specifically, the accumulation of
messenger and genomic virus-specific RNAs was reduced
by SFPQ/PSF silencing in infected cells. Furthermore,
transcription of parental ribonucleoproteins was affected
by SFPQ/PSF down-regulation. The consequences of
silencing SFPQ/PSF on the transcription and replication
of a viral recombinant replicon indicated that it is required
for virus transcription but not for virus RNA replication. In
vitro transcription experiments indicated that SFPQ/PSF
increases the efficiency of virus mRNA polyadenylation.
This is the first description of a cellular factor essential for
influenza virus transcription and opens the possibility to
identify inhibitors that target this host-virus interaction
and block virus gene expression.
Figure 1. Accumulation and localisation of SFPQ/PSF in
influenza virus infected cells. Cultures of human A549 cells were
infected with the VIC strain of influenza virus at 3 pfu/cell. (A) At the
times after infection indicated (hours), extracts were prepared and
analysed by Western-blot with the antibodies indicated to the right. (B)
At the same times, cultures were fixed and processed for immunoflu-
orescence using antibodies specific for SFPQ/PSF and NP, as indicated.
doi:10.1371/journal.ppat.1002397.g001
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whereas the progressive accumulation of virus proteins was
apparent (see NP marker in Figure 1A). Similar experiments were
obtained when the WSN virus strain was used (data not shown).
The localisation of SFPQ/PSF was analysed by confocal
immunofluorescence and is presented in Figure 1B. The protein
was found in a punctuate pattern within the nucleus, slightly more
intense in the nuclear periphery and excluded from the nucleoli.
No significant change could be observed in such distribution along
virus infection, although a small increase in cytoplasmic staining
was apparent at late times (Figure 1B). Similar results were
obtained using the HeLa cell line and the WSN virus strain (data
not shown).
SFPQ/PSF is specifically required for efficient influenza
virus infection
In previous studies we analysed the localisation of SFPQ/PSF
and NP by confocal immunofluorescence of cells infected with VIC
influenza virus. A clear co-localisation was observed at 4–6 hours
post-infection (hpi), particularly prominent at the periphery of the
cell nucleus [34]. To further analyse this association in infected cells
we carried out co-immunoprecipitation experiments. Cultures of
A549cellswereinfected athigh moiwiththe VICstrainofinfluenza
virus and at various times after infection cell extracts were prepared
and used for immunoprecipitation with anti-SFPQ/PSF or control
antibodies. The immunoprecipitates were analysed by Western-
blotting with antibodies specific for SFPQ/PSF and NP. The results
are presented in Figure 2 and a clear co-immunoprecipitation of NP
was observed with the SFPQ/PSF-specific antibodies. In view of
these results, the relevance of SFPQ/PSF for influenza virus
multiplication was then studied by gene silencing. Cultures of A549
cells were transfected with SFPQ/PSF-specific siRNA, or a
scrambled unspecific siRNA as a control, and then infected with
VIC influenza virus at low multiplicity. Samples were withdrawn
from the supernatant medium at various times after infection and
the virus titre was determined by plaque-assay on MDCK cells. The
results of kinetics experiments run in triplicate are presented in
Figure 3A. A protracted virus growth kinetics was apparent in the
SFPQ/PSF–silenced cultures as compared to cultures transfected
with control siRNA and the final titre was reduced by 2–3 log units
in various experiments similar to that presented in Figure 3A. The
level of SFPQ/PSF down-regulation was verified at various times
after siRNA transfection and virus infection and is presented in
Figure 3D. These results suggested that SFPQ/PSF plays an
Figure 2. Association of viral ribonucleoproteins with SFPQ/
PSF. Cultures of human A549 cells were infected with the VIC strain of
influenza virus at 3 pfu/cell. Total cell extracts were prepared at the
times after infection indicated (hpi) and immunoprecipitated with anti-
SFPQ/PSF or control antibodies. The immunoprecipitates were analysed
by Western-blot using antibodies specific for SFPQ/PSF or NP, as
indicated. I: Input extract. C: Control antibody. S: SFPQ/PSF specific
antibody.
doi:10.1371/journal.ppat.1002397.g002
Figure 3. Kinetics of influenza virus multiplication in SFPQ/
PSF-silenced cells. Cultures of human A549 cells were transfected
with SFPQ/PSF-specific or control siRNAs as described under Materials
and Methods and then infected with influenza virus at a moi of 0.001
pfu/cell. Aliquots of the supernatant media were withdrawn at the
times indicated and used for virus titration by plaque-assay. The results
presented are representative of two/three independent experiments.
(A) Cultures were silenced with control siRNA (blue) or siRNA-1 (red) and
infected with the VIC strain. (B) Cultures were silenced with control
siRNA (blue), siRNA-1 (red) or siRNA-2 (grey) and infected with a
recombinant virus containing the M, HA and NA segment of WSN in the
background of VIC strain. (C) Cultures were silenced with control siRNA
(blue), siRNA-1 (red) or siRNA-2 (grey) and infected with WSN strain. (D)
At the times after infection indicated (days), the accumulation of SFPQ/
PSF was determined in the cultures transfected with control (C) or
SFPQ/PSF siRNAs (S1 or S2, as indicated) by Western-blot using anti
SFPQ/PSF antibodies.
doi:10.1371/journal.ppat.1002397.g003
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virus growth inhibition is really due to SFPQ/PSF down-regulation
and not to an spurious off-target effect of the particular siRNA used,
similar experiments were performed with an independent SFPQ/
PSF-specific siRNA and the results are presented in Figure 3B and
3C. Furthermore, two additional virus strains were used in these
experiments, WSN and a VIC/WSN recombinant virus. Again, a
strong reduction in the yield of virus production was obtained,
thereby confirming that SFPQ/PSF in an important human host
factor for the multiplication of influenza virus.
AsSFPQ/PSFisamultifunctionalproteininvolvedinmanysteps
of cellular transcription and post-transcriptional RNA processing
[37], it is conceivable that its down-regulation indirectly leads to
reductions in influenza virus multiplication. For instance, it would
be conceivable that SFPQ/PSF down-regulation inhibits cellular
transcription and/or splicing to a level that makes influenza virus
unable to replicate, as it depends on these processes for its own
transcription and gene expression. Such a possibility would seem
unlikely, as the general pattern of cellular protein synthesis is not
altered by SFPQ/PSF silencing (see below), but we carried out
controls to ascertain the specificity of SFPQ/PSF requirement for
influenza virus multiplication. The multiplication of two additional
viruseswas studied in SFPQ/PSF-silenced cells:Vesicularstomatitis
virus (VSV), as an additional example of negative-stranded RNA
virus, and Adenovirus 5 (Ad5), as a nuclear virus that is strongly
dependent on the cellular transcriptional and splicing machineries.
Cultures of A549 cells were SFPQ/PSF- or control-silenced and
infected with either VSV or Ad5 and the virus accumulated in the
culture supernatant (VSV) or the infected cells (Ad5) was
determined by plaque-assay on BHK21 (VSV) or HEK293T cells
(Ad5). As presented in Figure 4A and 4B, the multiplication of
neither virus was affected by the down-regulation of SFPQ/PSF,
indicating that this human protein is a host factor specifically
important for influenza virus multiplication.
Since it has been shown that SFPQ/PSF associates to p54nrb/
NonO (see above), it was important to ascertain whether influenza
virus requires SFPQ/PSF or the SFPQ/PSF-p54nrb/NonO
heterodimer for proper multiplication. Hence, we analysed the
multiplication of influenza virus in A549 cells after silencing
p54nrb/NonO by transfection of a p54nrb/NonO-specific siRNA.
Importantly, silencing of p54nrb/NonO did not alter the
accumulation of SFPQ/PSF or vice versa (data not shown). As
indicated in Figure 5, no reduction in virus yield was observed
when using the VIC virus strain (Figure 5A) and a small reduction
in WSN virus amplification was observed by down-regulation of
p54nrb/NonO, much more limited than that observed when
silencing SFPQ/PSF (Figure 5B), in spite of an almost complete
block of p54nrb/NonO expression (Figure 5C). Therefore, we
conclude that it is SFPQ/PSF by itself what influenza virus
requires carrying out a normal infection cycle.
Down-regulation of SFPQ/PSF reduces virus RNA
replication and gene expression
Once the relevance of SFPQ/PSF for influenza virus infection
was verified, we analysed the role of this host factor in the virus
cycle. First, the synthesis of viral proteins was studied in SFPQ/
PSF- and control-silenced A549 cells. Cultures of SFPQ/PSF- or
control-silenced A549 cells were infected at high multiplicity and
pulse-labelled with
35S-met-cys at various times after infection.
The labelled proteins were analysed by polyacrylamide gel
electrophoresis and autoradiography and the results are presented
in Figure 6. The synthesis of the major virus proteins was reduced
and delayed in SFPQ/PSF-silenced cells, indicating that SFPQ/
PSF down-regulation leads to a general reduction and delay in
virus gene expression. However, it is worth mentioning that only a
slight change was observed in the level and pattern of cellular
protein synthesis upon SFPQ/PSF silencing (compare lanes 0 in
siCRTL and S1 panels in Figure 6). Similar results were obtained
when the accumulation of viral proteins was determined by
Western-blot (Figure S1).
To analyse further the phenotype of the infection cycle in SFPQ/
PSF-silenced cells, the localisation of progeny RNPs was studied by
confocal immunofluorescence with anti-NP antibodies. The results
are presented in Figure 7. As expected, the level of SFPQ/PSF was
decreased in SFPQ/PSF-silenced cells and a general reduction in
NP signal wasobserved,as compared withinfected,control-silenced
cells(Figure7A).Only cellswith a level ofSFPQ/PSF similar to that
of control-silenced cells showed an accumulation of NP comparable
to control infected cells, although the localisation was not normal
(Figure 7A; arrow). Significantly, a linear correlation was observed
between the immunofluorescence signals of SFPQ/PSF and NP in
random fields of control- or SFPQ/PSF-silenced cells (Figure 7B).
Thus, the low levels of virus protein synthesis (Figure 6) and the
Figure 4. Kinetics of VSV and Ad5 multiplication in SFPQ/PSF-
silenced cells. Cultures of human A549 cells were transfected with
SFPQ/PSF-specific siRNA-1 (S1) or control (C) siRNAs, infected with VSV
or Ad5 as described under Materials and Methods and virus titration
was performed with samples obtained at the times indicated. The
results presented are representative of two/three independent exper-
iments. (A) Cultures were silenced with control siRNA (blue) or siRNA-1
(red) and infected with VSV at a moi of 0.001 pfu/cell. (B) Cultures were
silenced with control siRNA (blue) or siRNA-1 (red) and infected with
Ad5 at a moi of 2 pfu/cell. (C) At the times after infection indicated
(days), the accumulation of SFPQ/PSF was determined in the cultures
transfected with control (C) or SFPQ/PSF siRNAs (S1) by Western-blot
using anti SFPQ/PSF antibodies.
doi:10.1371/journal.ppat.1002397.g004
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cultures could be simply the consequence of the infection of a small
number of cells not completely silenced upon transfection of SFPQ/
PSF-specific siRNA.
Viral transcription, but not splicing, is affected in SFPQ/
PSF silenced cells
The reduction of virus protein synthesis under conditions of
SFPQ/PSF down-regulation might be due to defects in genome
amplification, virus transcription, splicing or translation of viral
mRNA. As SFPQ/PSF has been described as a splicing factor, we
first analysed whether its down-regulation would alter the splicing
of virus mRNAs. The amounts of NS1 and NS2 mRNAs were
determined in control and SFPQ/PSF silenced infected cells by a
RT-qPCR procedure using TaqMan probes (Table S1). The
proportion of NS1 versus total NS mRNA was indistinguishable in
both experimental conditions (ratio control/silenced cells 1.016+/
20.035; n=7 experiments). Next, the levels of accumulation of
vRNA, cRNA and mRNA were determined in SFPQ/PSF-
silenced and control-silenced cells. Total cell RNA was isolated at
various times after high-multiplicity infections and the amounts of
virus-specific RNAs corresponding to the NP, NS and M virus
segments were determined by hybridisation with specific probes.
The results of a representative experiment are presented in
Figure 8. In control-silenced cells, the kinetics of accumulation of
virus RNAs showed a pattern analogous to that previously
described [56,57], while in SFPQ/PSF-silenced cells a protracted
kinetics was observed and 4-5 fold reductions in maximal
accumulations of vRNA, cRNA and mRNA were determined.
These results indicated that SFPQ/PSF is required for virus RNA
replication but could not tell whether this was a direct effect and
whether SFPQ/PSF also played a role in virus transcription. To
clarify these questions, the accumulations of primary virus
transcripts were determined after infection of SFPQ/PSF-silenced
and control-silenced cells. The cells were infected at high
multiplicity in the presence of cycloheximide to avoid the synthesis
of viral proteins and hence the replication of viral RNA [58]. The
accumulation of total NS transcripts was determined by RT-qPCR
and demonstrated that silencing SFPQ/PSF leads to a 3-fold
reduction in primary transcription (Figure 9A). To verify the
inhibition of virus multiplication, virus mRNA was determined in
infected cells treated or not with cycloheximide. The results are
presented in Figure 9B and document around 50-fold reduction
upon treatment with the drug.
These results suggest that SFPQ/PSF might simply be required
for virus primary transcription and the observed reduction in
vRNA accumulation would be an indirect consequence, since viral
protein expression is essential for viral RNA replication [58]. To
Figure 5. Kinetics of influenza virus multiplication in NonO-
silenced cells. Cultures of human A549 cells were transfected with
NonO-specific (N1 or N2, as indicated) or control (C) siRNAs as described
under Materials and Methods and then infected with influenza virus at a
moi of 0.001 pfu/cell. Aliquots of the supernatant media were
withdrawn at the times indicated and used for virus titration by
plaque-assay. The results presented are representative of two/three
independent experiments. (A) Cultures were silenced with control
siRNA (blue), siRNA N1 (green) or siRNA N2 (yellow) and infected with
the VIC strain. (B) Cultures were silenced as above and infected with
WSN virus. (C) At the times after infection indicated (days), the
accumulation of NonO/p54 was determined in the cultures transfected
with control (C) or SFPQ/PSF siRNAs (N1 or N2, as indicated) by
Western-blot using anti NonO/p54 antibodies.
doi:10.1371/journal.ppat.1002397.g005
Figure 6. Kinetics of influenza virus protein synthesis in SFPQ/
PSF-silenced cells. Cultures of human A549 cells were transfected
with SFPQ/PSF-specific siRNA-1 (S1) or control siRNA (siCTRL) as
described under Materials and Methods and then infected with VIC
virus at a moi of 3 pfu/cell. At the times in hours indicated the cultures
were pulse-labelled with
35S-met-cys and total protein extracts were
prepared. The samples were analysed by polyacrylamide gel electro-
phoresis and autoradiography. The mobility of some of the virus-
specific proteins is indicated to the right.
doi:10.1371/journal.ppat.1002397.g006
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PSF down-regulation, in addition to the observed inhibition of
primary transcription, we made use of a recombinant replicon
system to analyse RNA replication and secondary transcription. In
this system, no primary transcription is required for RNA
replication to take place, as the virus proteins are provided by
plasmid expression in trans. Human HEK293T cells were
transfected with SFPQ-specific or control siRNAs and later
transfected with plasmids encoding the virus polymerase subunits,
NP and a virus genomic plasmid encoding the cat gene in negative
polarity. The down-regulation of SFPQ/PSF was ascertained by
Western-blot (Figure 10D) and the CAT protein accumulation was
determined as a reporter of total replicon activity. The results
indicated that silencing SFPQ/PSF lead to a 5-fold reduction in
CAT expression (Figure 10A). To determine whether this
reduction was due to alterations in viral RNA replication,
transcription or both, total cell RNA was isolated and used to
determine negative-polarity and positive-polarity RNA accumula-
tions by hybridisation with specific probes. As shown in
Figure 10B, a 5-fold reduction in viral transcription was apparent,
whereas a two-fold increase was observed between the accumu-
lations of vRNA in control or SFPQ/PSF-silenced cells
(Figure 10C). These results indicated that SFPQ/PSF is required
for viral transcription, but not for virus RNA replication and
suggest that, in the absence of SFPQ/PSF, the viral RNPs are
preferentially devoted to RNA replication instead of transcribing
their template.
Figure 7. Cytological analysis of influenza virus infection of
SFPQ/PSF-silenced cells. Cultures of human A549 cells were
transfected with control siRNA (C) or SFPQ/PSF-specific siRNAs (S1 or
S2 as indicated), as described under Materials and Methods, and then
infected with VIC virus at a moi of 3 pfu/cell. The cultures were fixed at
6 hpi and processed for immunofluorescence using antibodies specific
for SFPQ/PSF and NP. (A) The images presented are representative
confocal sections showing the presence of nuclei (DAPI –blue-), SFPQ/
PSF (red) and NP (green). (B) Graphical representation of the NP (vertical
axis) and SFPQ/PSF (horizontal axis) signals obtained for random
1024x1024 images of each sample. Blue: Control-silenced cultures. Red:
SFPQ/PSF-silenced cultures (S1). Grey: SFPQ/PSF-silenced cultures (S2).
The black dot indicates the background signals obtained for cultures
stained with the secondary antibodies only.
doi:10.1371/journal.ppat.1002397.g007
Figure 8. Accumulation of positive- and negative-polarity
RNAs during the influenza virus infection of SFPQ/PSF-silenced
cells. Cultures of human A549 cells were transfected with SFPQ/PSF-
specific (S1) or control siRNAs (siCTRL) as described under Materials and
Methods and then infected with influenza virus at a moi of 3 pfu/cell.
Total cell RNA was isolated at the times indicated and used for
determination of vRNA (A) cRNA (B) or mRNA (C) by hybridisation with
probes specific for NP (blue), NS (yellow) and M (red). The data is
presented as percent of maximal values and is representative of three
independent kinetics experiments.
doi:10.1371/journal.ppat.1002397.g008
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viral polyadenylated RNA in vitro
One possible mechanism to explain the effects of SFPQ/PSF
down-regulation on influenza virus transcription would imply that
the interaction of SFPQ/PSF with the viral polymerase present in
the RNP increases the affinity of the enzyme for the cap structure.
The apparent Kd for the interaction of the isolated PB2 cap-
binding domain with 7mGTP is around 170 mM [10], in good
agreement with the inhibition data reported for cap-RNA
crosslinking to influenza virus RNPs [59], whereas the affinity of
binding of eIF4E or CBC to cap-analogues is much higher
[60,61]. This is in contradistinction to the elution profiles of eIF4F
and influenza polymerase-template complexes on a 7mGTP-
Sepharose resin [14] which show a stronger binding of the latter.
Hence, it is conceivable that some cellular factor(s), for instance
SFPQ/PSF, interact with viral polymerase and enhances its
affinity for binding to cap. To test such possibility we generated
recombinant RNPs by transfection of HEK293T cells, which had
previously been either control- or SFPQ/PSF-silenced. Total cell
extracts of these cells were used for in vitro transcription using ß-
globin mRNA as cap-donor. A wide concentration range of cap-
donor was employed to test for a potential difference in cap-donor
dose response when the reaction was performed in the presence or
absence of SFPQ/PSF protein. The results are presented in
Figure 11 and no change in the profile of virus RNA synthesis was
apparent when SFPQ/PSF was silenced (Figure 11B). However, a
clear change in the size distribution of RNA products was
observed depending on the downregulation of SFPQ/PSF and
irrespective of the cap-donor concentration (Figure 11A). In the
presence of SFPQ/PSF the RNA profile was reminiscent of a
polyadenylated virus mRNA, as the transcript size was slightly
larger than the template (used in the gel as a marker) while
downregulation of SFPQ/PSF led to a variety of RNA sizes,
always smaller than the template. To further characterise the
transcripts generated with SFPQ/PSF-silenced samples they were
separated into poly A
+ and poly A
2 fractions and analysed by
denaturing polyacrylamide gel electrophoresis. The results are
presented in Figure 12. A consistent reduction in the amount of
polyadenylated RNA was observed when SFPQ/PSF was
downregulated, with a corresponding increased in the poly A
2
fraction (Figure 12A). Quantification of 5 experiments indicated
that the total amount of transcript was not affected by SFPQ/PSF
downregulation but the fraction of poly A
+ viral mRNA was
reduced about 4–5 fold (Figure 12 B). Similar results were
obtained when other SFPQ/PSF-specific siRNA was used (see
Figure S2). A considerable fraction of the viral poly A
2 transcrips
showed sizes smaller than the template, consistent with RNA
degradation or premature termination but, interestingly, the
profile of these poly A
2 transcripts was identical for control- or
SFPQ/PSF-silenced samples, suggesting that the reduction in poly
A
+ transcripts is not due to a defect in transcript elongation but
most probably to a deficiency in the polyadenylation step.
Concluding remarks
The results presented here show that SFPQ/PSF is specifically
required for influenza virus multiplication and indicate that this
cellular factor is essential for the transcription of viral RNPs during
both primary and secondary mRNA synthesis. Furthermore, the
results shown suggest that SFPQ/PSF plays a role during the
polyadenylation step in virus transcription. With the evidence
presented, the following picture could be envisaged upon SFPQ
down-regulation in infected cells: The primary viral mRNAs
lacking poly A would be unstable and hence their accumulation
diminished as compared to infections performed in normal cells.
In addition, normal recycling of the transcribing polymerase could
be affected. As a consequence of these effects, viral RNA
replication would be indirectly inhibited, since little polymerase
and NP would be synthesised. Moreover, a similar inhibition could
be predicted for secondary transcription of the small amount of
viral progeny RNA, with the final result of very low viral gene
expression and virus production.
At present it is not clear how SFPQ/PSF participates in the
polyadenylation step of viral transcription. The available evidence
indicates that polyadenylation of viral mRNAs is carried out by the
polymerase by reiterative copy of the oligo U signal located close
to the 59-terminus of the vRNA template [62–65] and is
mechanistically distinct from the cellular cleavage and polyade-
nylation process. The SFPQ/PSF protein is an RNA-binding
protein that has been described as essential for the formation of the
spliceosome and can be cross-linked to the pre-mRNA in the
spliceosome [46]. Furthermore, purified SFPQ/PSF can be
specifically cross-linked to poly U, but not to poly C, A or G,
showing the same sequence specificity than PTB [38]. Therefore,
it is tempting to speculate that SFPQ/PSF could interact both with
the viral polymerase [34] and with the viral polyadenylation signal
Figure 9. Accumulation of mRNA during the influenza virus
infection of SFPQ/PSF-silenced cells treated with cyclohexi-
mide. Cultures of human A549 cells were transfected with SFPQ/PSF-
specific (S1) or control siRNAs (siCTRL) as described under Materials and
Methods and then infected with influenza virus at a moi of 3 pfu/cell for
6 hours in the presence or absence of cycloheximide (100 mg/ml). The
accumulation of viral RNA was determined by RT-qPCR using probes
specific for the NS segment. Significance was determined by the
Student’s t test. (A) The accumulation of viral RNA in control and SFPQ/
PSF-silenced cells treated with cycloheximide is presented as average
and standard deviation of 6 determinations. (B) The accumulation of
mRNA in infected cells treated or not with cycloheximide is presented
as average and standard deviation of 6 determinations.
doi:10.1371/journal.ppat.1002397.g009
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Further experiments will be required to test this and other possible
alternatives.
Down-regulation of SFPQ/PSF leads to a dramatic decrease in
the yield of virus infection and hence it could be considered as a
new target for antiviral design, a particularly interesting one as it is
involved in a very early stage of the infection. Silencing of mouse
SFPQ/PSF leads to chromosome instability [66] and we have
verified that down-regulation of SFPQ/PSF in some human cells
strongly reduces their growth kinetics (unpublished results).
Therefore, one should aim at blocking the association of SFPQ/
PSF with virus polymerase/RNP for the design of potential new
antivirals.
Materials and Methods
Biological materials
The HEK 293T cell line [67] was obtained from J.C. de la
Torre and the A549 human cell line [68] was obtained from J.A.
Melero. The MDCK and BHK21 cell lines were purchased from
ATCC. Cell culture was carried out as described [69]. The
influenza virus strains A/Victoria/3/75 (H3N2) (VIC), WSN
(H1N1) and a recombinant of both strains (VIC/WSN) was used
in these experiments. Titrations were done in MDCK cells as
described [70]. Vesicular stomatitis virus (VSV) was provided by
R. Alfonso and titrated in BHK21 cells. Adenovirus 5 was
provided by P. Fortes. Virus stocks were prepared and titrated in
HEK 293T cells as described [71].
Plasmids pCMVPB1, pCMVPB2, pCMVPA and pCMVNP,
expressing the influenza virus polymerase subunits and the NP
have been described [57]. Plasmid pHHCAT, that transcribes a
virus-like cat gene in negative polarity, was provided by A.
Rodrı ´guez. The monoclonal antibodies specific for PA have been
described [72,73]. A monoclonal antibody specific for the N-
terminal region of M1 and M2 proteins [74] was provided by A.
Garcı ´a-Sastre. Antisera specific for PB1 and NP were generated by
immunisation of rabbits with recombinant proteins [2,14,31]. A
monoclonal antibody specific for SFPQ/PSF (ab11825) and
polyclonal sera specific for GAPDH (ab9485) and actin (ab8226)
were purchased to Abcam. The secondary antibodies used for
Western-blot and immunofluorescence was purchased to Sigma
and Invitrogen, respectively. Total mouse IgG, with no known
specificity, was used as immunoprecipitation control.
Protein analyses
Protein samples were separated by polyacrylamide-SDS gel
electrophoresis and transferred to Immobilon filters. Western-
blotting was carried out essentially as described [75]: The
membranes were saturated with 3% BSA for 1 h and then
Figure 10. Accumulation of positive- and negative-polarity
RNA in a recombinant replicon system. Cultures of HEK293T cells
were transfected with SFPQ/PSF-specific (S1) or control siRNAs (siCTRL)
as described under Materials and Methods. When the expression of
SFPQ/PSF was known to be down-regulated, the cultures were further
transfected with plasmids expressing the polymerase subunits and the
NP, as well as with a genomic plasmid expressing a pseudoviral gene
containing the cat gene in negative polarity. As control, the cultures
were transfected with empty plasmids. At 24 hours post plasmid
transfection total cell extracts were prepared and total cell RNA was
isolated. Significance was determined by the Student’s t test. (A) The
accumulation of CAT protein is indicated as percent of maximal values.
(B) The accumulation of positive-polarity RNA was determined by
hybridisation with CAT-specific probes and is presented as percent of
maximal values. (C) The accumulation of negative-polarity RNA was
determined by hybridisation with CAT-specific probes and is presented
as percent of maximal values. The values presented represent the
average and standard deviation of 3 independent transfection
experiments. (D) The silencing of SFPQ was controlled by Western-
blot, using actin as loading control. The level of expression of PA and
NP was ascertained by Western-blot.
doi:10.1371/journal.ppat.1002397.g010
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temperature. The filters were washed with PBS containing
0.25% Tween 20 and incubated with the appropriate secondary
antibody conjugated to horseradish peroxidase. After further
washing as above the filters were developed by enhanced
chemiluminiscence. For immunoprecipitations, extracts from
mock-infected or infected cells were incubated with goat-
antimouse-agarose beads (A6531, Sigma) loaded with a monoclo-
nal antibody specific for SFPQ/PSF or an equal amount of total
mouse IgG as negative control. After extensive washing with a
buffer containing 50 mM Tris HCl pH 7,5, 150 mM NaCl, 0,5%
NP-40, 1,5 mM MgCl2, 1 mM DTT, 1 u/ml HPRI and protease
inhibitors containing EDTA, the beads were extracted by boiling
with Laemmli loading buffer and the samples were analysed by
Western-blot with antibodies specific for SFPQ/PSF and NP. For
immunofluorescence, cells were fixed with 3% paraformaldehyde.
The cultures were permeabilised with 0.5% Triton X100 and
processed for indirect immunofluorescence as described before
[31]. Images were collected on a Leica SP5 confocal microscope
(Leica Microsystems) and processed with the LAS AF Software
(Leica Microsystems). For quantisation of cellular staining with
anti-SFPQ/PSF and NP antibodies, the average intensities of 50
random images (102461024 pixels) of each preparation were
determined using the LAS AF Software. The procedures for
protein labelling in vivo have been described [76]. Cultures were
washed, incubated for 1 h in a DMEM medium lacking met-cys
and labelled with
35S-met-cys to a final concentration of 200 mCi/
ml. After incubation for 1 h, total extracts were prepared in
Laemmli sample buffer and processed by polyacrylamide gel
electrophoresis and autoradiography. Quantisation of CAT
protein in total cell extracts was done by ELISA (GE Healthcare).
RNA analyses
The amplification in vivo of recombinant RNPs was performed
essentially as described [77]. In brief, cultures of HEK293T cells
(2.5 10
6 cells) were transfected with a mixture of plasmids
expressing the polymerase subunits (pCMVPB1, 12.5 ng;
pCMVPB2, 12.5 ng; pCMVPA, 2.5 ng), NP (pCMVNP,
500 ng) and a genomic plasmid expressing a vRNA-like cat gene
(pHHCAT, 500 ng), using the calcium phosphate technique [78].
At 24 hours post-transfection, total cell extracts were prepared for
CAT determination or total cell RNA was extracted. For RNA
extraction cell pellets were resuspended in 1 ml of TRIZOL
reagent (Invitrogen) and the RNA was purified as recommended
by the manufacturer. The RNA was digested with RNAse-free
DNAse (1 u/mg) for 1 h at 37uC, extracted with phenol-
chloroform-isoamylalcohol and precipitated with ethanol. For
alternative splicing studies, poly A
+ RNA was isolated by two
rounds of chromatography on oligo-dT-cellulose as described
previously [79]. The purified RNA was resuspended in nuclease-
free water and the absorbance was measured at 260 nm
(NanoDrop ND-1000).
Figure 11. Cap-donor dose-response for in vitro transcription of
recombinant RNPs. Cultures of HEK293T cells were transfected with
SFPQ/PSF-specific (S1) or control siRNAs (siCTRL) as described under
Materials and Methods. When the expression of SFPQ/PSF was known
to be down-regulated, the cultures were further transfected with
plasmids expressing the polymerase subunits and the NP, as well as
with a genomic plasmid expressing a deleted NS RNA segment (clone
23) [2] in negative polarity. Extracts of these cultures were used for in
vitro transcription using increasing amounts of ß-globin mRNA as a cap
donor and the transcripts were analysed by denaturing polyacrylamide
gel electrophoresis. (A) Denaturing polyacrylamide gel electrophoresis
of in vitro transcripts. M denotes a mock-reconstitution of recombinant
RNPs in which pcDNA3 plasmid was transfected. The concentrations
(mg/ml) of ß-globin mRNA used as cap-donor are indicated to the top.
The mobility of a genome-size marker of 248 nt is indicated to the right.
(B) The quantisation of the results presented in A is presented as
percent of maximal value in each series. Blue line: Control-silenced
extract. Red line: SFPQ/PSF-silenced extract. (C) The down-regulation of
SFPQ/PSF by silencing was verified by Western-blot with specific
antibodies. The level of expression of PA and NP was ascertained by
Western-blot.
doi:10.1371/journal.ppat.1002397.g011
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denatured for 15 min at 55uC in 10SSC, 7.5% formaldehyde and
fixed on nylon filters by UV cross-linking. As controls, total yeast
RNA or various amounts of plasmids containing cDNAs of the
full-length virus genomic segments or the corresponding viral
mRNAs, were fixed on the hybridisation filters. Hybridisation was
carried out overnight at 40uC in 6xSSC, 0.5% SDS, 56
Denhardt’s mixture 26–47% formamide, depending on the probe,
and 100 mg/ml single-stranded DNA. After washing with
0.5xSSC-0.5% SDS at 40uC, the filters were quantified in a
phosphorimager. As probes, synthetic oligonucleotides specific to
detect the various RNA species of each RNA segment analysed
were used (Table S1). They were labelled with gamma-
32P-ATP
and polynucleotide kinase. Additionally, specific riboprobes were
used to specifically detect cRNAs. They were transcribed by T3
RNA polymerase using as templates synthetic DNAs containing
T3 promoters fused to the viral sequences (Table S1).
For siRNA transfection, cultured A549 cells were incubated
independently with 5 nM of siSFPQ 1 (107613), siSFPQ 2
(15923), specific for SFPQ, or siNonO 1 (s9614), siNonO 2
(s9612), specific for NonO, or an irrelevant siRNA (AM4611) from
Ambion, using Lipofectamine (Invitrogen) as recommended by the
manufacturer. Transfection was carried out twice on consecutive
days to increase the silencing efficiency before infection.
Quantification of virus-specific RNAs for splicing and primary
transcription analyses was carried out by RT-qPCR as follows:
The RT reaction was performed by addition of 100 ng of RNA
resuspended in 10 ml of nuclease-free water and 10 ml of Reaction
Mix 2x (Applied Biosystems) as recommended by the manufac-
turer. From each 20-ml reaction, 2 ml of cDNA was transferred
directly to 96-well PCR plates and 12,5 ml of TaqMan universal
master mixture (Applied Biosystems) and 1,25 ml of Custom
TaqMan assay (designed by Applied BioSystems) were added.
PCR was carried out in a PRISM 7000 Sequence detection system
(Applied Biosystems), with 1 cycle of 50uC for 2 min followed by 1
cycle of 95uC for 10 min, 40 cycles of 95uC for 15 s and 60uC for
1 min. The cycle threshold (Ct) was determined with analytical
software (SDS; Applied Biosystems). Serial dilutions of cDNA were
used to ensure amplification in the lineal range. To construct
calibration curves for quantification, we generated PCR products
whose sequences were identical to the spliced or unspliced mRNAs
of NS segment. The sequences of TaqMan probes and primers are
presented in Table S1. For in vitro transcription, extracts from
control- or SFPQ/PSF-silenced HEK293T cells in which a mini-
RNP was reconstituted [2] were incubated for 60 min at 30uCi n
20 ml reactions containing 50 mM Tris.HCl, 100 mM KCl,
2 mM MgCl2, 1 mM DTT, 1 mM each of ATP, CTP and
UTP, 1 mM alpha-
32P-GTP (0.5 mCi/mmol), 10 mg/ml actino-
mycin D, 1 u/ml HPRI, pH 8.0 and mg/ml (or various amounts,
depending on the experiment) ß-globin mRNA. The reaction
products were phenol-extracted, ethanol-precipitated and ana-
lysed by electrophoresis on 6% polyacrylamide-7 M urea gels. The
purified in vitro transcripts were separated into poly A
+ and poly
A
2 fractions by chromatography on oligo dT-cellulose as
described [80]. To monitor the recovery of RNAs during
extraction and fractionation two labelled synthetic oligonucleo-
tides were added, a 50 nt oligonucleotide lacking poly T sequences
and a 70 nt long containing a 39T tract at its 39-terminus.
Supporting Information
Figure S1 Accumulation of viral proteins during influ-
enza virus infection of SFPQ/PSF-silenced cells. Cultures
of human A549 cells were transfected with SFPQ/PSF-specific
Figure 12. Dependence of SFPQ/PSF for the in vitro polyade-
nylation of transcripts. Recombinant RNPs were generated in
control-silenced (C) or SFPQ/PSF-silenced (S1) HEK293T cells and in
vitro transcription was performed as indicated in the legend to
Figure 11. The transcripts were separated into poly A
+ and poly A
2
fractions, using a non-polyadenylated oligonucleotide (50 nt) and a
polyadenylated oligonucleotide (70 nt) as recovery probes, and the
fractionated transcripts were analysed by electrophoresis on denaturing
polyacrylamide gels. (A) Representative results of five independent
experiments. The positions of a 248 nt marker identical to the clone 23
genome, as well as the recovery probes are indicated to the left. (B)
Quantification of the proportion of the poly A
+ (blue) and poly A
2
(yellow) transcripts after normalisation for recovery. The data represent
averages and standard deviations of five experiments. Significance was
determined by the Student’s t test. (C) The silencing of SFPQ was
controlled by Western-blot, using actin as loading control. The level of
expression of PA and NP was ascertained by Western-blot.
doi:10.1371/journal.ppat.1002397.g012
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Methods and then infected with influenza virus at a moi of 3 pfu/
cell. At the times after infection indicated, total cell extracts were
prepared and used for Western-blot with the antibodies indicated
to the right.
(TIF)
Figure S2 Dependence of SFPQ/PSF for the in vitro
polyadenylation of transcripts. Recombinant RNPs were
generated in control-silenced (C) or SFPQ/PSF-silenced (S2)
HEK293T cells and in vitro transcription was performed as
indicated in the legend to Figures 11 and 12. The transcripts were
separated into poly A
+ (blue) and poly A
2 (yellow) fractions, using
a non-polyadenylated oligonucleotide (50 nt) and a polyadenylated
oligonucleotide (70 nt) as recovery probes, and the fractionated
transcripts were analysed by electrophoresis on denaturing
polyacrylamide gels. (A) Representative results of two independent
experiments. The positions of a 248 nt marker identical to the
clone 23 genome, as well as the recovery probes are indicated to
the left. (B) Quantification of the proportion of the poly A
+ and
poly A
2 transcripts after normalisation for recovery. The data
represent averages and ranges of two experiments. (C) The
silencing of SFPQ was controlled by Western-blot, using actin as
loading control. The proper reconstitution of recombinant RNPs
was ascertained by Western-blot with antibodies specific for PA
and NP.
(TIF)
Table S1 Oligonucleotides used as probes for detection
of viral RNAs. The Table shows the sequences of the
oligonucleotides used as probes for hybridisation to vRNAs,
mRNAs and cRNAs, corresponding to the M, NP and NS
segments as indicated. The length of the probes and the
concentration of formamide used during the hybridisation
reactions are also indicated. Likewise, the sequences used for
amplification of NS1 mRNA (NS1 intron), NS2 mRNA (NS2
border) and total NS mRNAs (Total NS) are indicated, as well as
the corresponding Taqman probes.
(PDF)
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